Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
about
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trialPrion diseases: immunotargets and therapyEffective gene therapy in a mouse model of prion diseasesTreatment of Prion Disease with Heterologous Prion ProteinsSystematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditionsPostmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate.Diphenylpyrazole-derived compounds increase survival time of mice after prion infection.Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugsActivation of pro-survival CaMK4β/CREB and pro-death MST1 signaling at early and late times during a mouse model of prion disease.Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?Rapidly progressive dementias and the treatment of human prion diseases.Recent advances in prion chemotherapeutics.Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture SystemMechanistic insights into the cure of prion disease by novel antiprion compoundsPrion strain- and species-dependent effects of antiprion molecules in primary neuronal culturesTherapeutic approaches for prion disorders.Prions: Beyond a Single Protein.Therapies for human prion diseasesSmall-molecule theranostic probes: a promising future in neurodegenerative diseases.Therapeutic interventions ameliorating prion disease.Doxycycline in early CJD: a double-blinded randomised phase II and observational study.Biochemical and strain properties of CJD prions: complexity versus simplicity.Insights from Therapeutic Studies for PrP Prion Disease.Developing Therapeutics for PrP Prion Diseases.Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease.Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.Clinical trials for prion disease: difficult challenges, but hope for the futureThe celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.Recombinant PrP and Its Contribution to Research on Transmissible Spongiform Encephalopathies.
P2860
Q24653364-05FBEEDA-1BBA-4297-8371-F48AA8D86E3DQ26741258-1354DAD4-5FC5-471C-B565-A841C8CA5FC3Q27300832-06867F42-7D48-4A8D-9EA7-AFB31A3B65A6Q27303161-8D49A994-CAD5-41B7-B9DE-C7AFBAA2944AQ28075766-56E5BE32-5E28-4F2F-8AE6-5EE179A01706Q33956775-A020AEF4-05FC-4F50-AB0B-31DD807ECFFEQ33957528-BD0ACCFC-FE3E-4F70-A4DB-61F143A7F519Q34120213-C2F1BE31-2005-437B-9261-DFD866A3937FQ34207678-98C2673C-D415-42A5-813E-B6B28D742BD8Q34415659-B7AE2758-28A7-49F2-9FAB-D5EAC6579381Q34625274-14849309-0913-46D8-BD51-62791F1F9F28Q35832931-7D12333A-EC85-487A-BE2F-48AF75A607B3Q35944199-003B8A96-7F62-4867-B806-47D0E656AE71Q36068573-C182A7A4-6ABB-4542-8C68-C684AF14369EQ36099134-EFC5A593-706F-49A2-B78D-3060554C16EEQ36315218-65740216-2DAB-406A-A083-908397DF27F2Q36901944-13930ED6-415B-4291-966B-45E2F77D4618Q37162363-E849EEC4-6FF6-4EE1-AB2A-67012FD2CCD4Q37199225-DBC793AF-661D-422A-9655-31D0913F7C20Q37353880-B47353DE-D092-402F-9CF6-1CDA690BD1A8Q37557690-2F58A09A-D992-48E8-AFD4-15CF55D491EDQ37617090-21BB5ABC-D0D6-46B6-B453-FC24FACBAAFAQ37905853-ED8E4412-5BC6-4403-9E22-047BD9894339Q39005891-AA3962E1-18C5-4259-8276-964296074EA4Q39092621-F438A2ED-B541-4E2E-AAD8-6E73FAAA8E11Q39620546-3DCF6787-F8AB-4539-A35C-532815460D75Q41150193-53686571-8662-40AE-88FA-2CDF0D984E60Q42576622-60C99C7B-3512-4E20-B5CB-D95807A16A32Q46240779-191317CA-B8E7-4B26-95BA-C8632669519BQ47294251-48EA4252-3C4E-4DFB-B207-E1E7840EB20E
P2860
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Compassionate use of quinacrin ...... s to show significant effects.
@ast
Compassionate use of quinacrin ...... s to show significant effects.
@en
Compassionate use of quinacrin ...... s to show significant effects.
@nl
type
label
Compassionate use of quinacrin ...... s to show significant effects.
@ast
Compassionate use of quinacrin ...... s to show significant effects.
@en
Compassionate use of quinacrin ...... s to show significant effects.
@nl
prefLabel
Compassionate use of quinacrin ...... s to show significant effects.
@ast
Compassionate use of quinacrin ...... s to show significant effects.
@en
Compassionate use of quinacrin ...... s to show significant effects.
@nl
P2093
P1433
P1476
Compassionate use of quinacrin ...... s to show significant effects.
@en
P2093
Alpérovitch A
Belorgey C
Brandel JP
Delasnerie-Lauprêtre N
Faucheux BA
Laplanche JL
P304
P356
10.1212/01.WNL.0000148596.15681.4D
P407
P577
2004-12-01T00:00:00Z